Hodgkin's lymphoma (HL), impacting the lymph nodes and lymphatic system, has experienced a gradual increase in survival rates thanks to contemporary chemotherapy. However, challenges persist for patients who exhibit resistance to initial treatments or suffer relapses, highlighting an urgent demand for more potent therapeutic solutions. The intricacies of early-stage versus advanced disease management further necessitate a nuanced treatment approach that can effectively tackle these complexities.
The Department of Lymphoma at Tianjin Medical University Cancer Institute & Hospital has delivered a thorough update on HL treatments in the journal . explores the latest advancements in HL therapeutic regimens, offering a beacon of hope for the medical community and patients alike. This study meticulously dissects the progression of HL treatment strategies, with a particular emphasis on the burgeoning role of immunotherapies.
Brentuximab vedotin (BV), an antibody-drug conjugate, has demonstrated exceptional efficacy when combined with doxorubicin, vinblastine, and dacarbazine (AVD) chemotherapy, achieving higher PET-negative rates and enhanced two-year PFS rates. The study also highlights the efficacy of PD-1 antibodies in advanced HL, showcasing a notable increase in (PFS) and a reduction in treatment-related toxicities. Moreover, personalized therapies guided by PET2 imaging have been identified as a promising avenue, yielding remarkable three-year PFS rates and advocating for a mo.